JPWO2020038415A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020038415A5 JPWO2020038415A5 JP2021509151A JP2021509151A JPWO2020038415A5 JP WO2020038415 A5 JPWO2020038415 A5 JP WO2020038415A5 JP 2021509151 A JP2021509151 A JP 2021509151A JP 2021509151 A JP2021509151 A JP 2021509151A JP WO2020038415 A5 JPWO2020038415 A5 JP WO2020038415A5
- Authority
- JP
- Japan
- Prior art keywords
- piperazin
- pyrrolidin
- pyridazin
- imidazo
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 4
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- GSAFGEITCNSCAJ-YTKQHNFLSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[3-[[4-[6-[6-[(2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]piperazin-1-yl]methyl]pyrrolidin-1-yl]isoindole-1,3-dione Chemical compound C1C[C@@H](N(C1)C2=NN3C(=NC=C3C4=NC(=CC=C4)N5CCN(CC5)CC6CCN(C6)C7=CC8=C(C=C7)C(=O)N(C8=O)C9CCC(=O)NC9=O)C=C2)C1=CC(=CC=C1)F GSAFGEITCNSCAJ-YTKQHNFLSA-N 0.000 claims 2
- GUXGUSYUJZREHG-KWRHIPAJSA-N 3-[5-[3-[4-[6-[6-[(2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]piperazin-1-yl]-3-oxoprop-1-ynyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC=1C=C(C=CC=1)[C@@H]1N(CCC1)C=1C=CC=2N(N=1)C(=CN=2)C1=CC=CC(=N1)N1CCN(CC1)C(C#CC1=CC=C2CN(C(C2=C1)=O)C1C(NC(CC1)=O)=O)=O GUXGUSYUJZREHG-KWRHIPAJSA-N 0.000 claims 2
- KORPLFDBDVBAFK-KWRHIPAJSA-N 3-[6-[3-[4-[6-[6-[(2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]piperazin-1-yl]-3-oxoprop-1-ynyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC=1C=C(C=CC=1)[C@@H]1N(CCC1)C=1C=CC=2N(N=1)C(=CN=2)C1=CC=CC(=N1)N1CCN(CC1)C(C#CC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O KORPLFDBDVBAFK-KWRHIPAJSA-N 0.000 claims 2
- RIYXRIJSDXMVNL-PBBFAOSKSA-N N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]-2-[4-[6-[6-[(2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]piperazin-1-yl]acetamide Chemical compound C1N(C2=NC(=CC=C2)C=2N3C(=NC=2)C=CC(N2[C@H](CCC2)C2=CC(F)=CC=C2)=N3)CCN(C1)CC(=O)NC1=CC=2C(=O)N(C(=O)C=2C=C1)C1C(=O)NC(=O)CC1 RIYXRIJSDXMVNL-PBBFAOSKSA-N 0.000 claims 2
- JIGZJNQMIOEJSM-UHFFFAOYSA-N N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino]ethyl]piperazin-1-yl]-2-(oxan-4-ylamino)benzamide Chemical compound C1C(NC2=C(C(=O)NC=3C4=CC(CC5=CC(F)=CC(F)=C5)=CC=C4NN=3)C=CC(N3CCN(CC3)CCNC3=CC=C4C(=C3)C(=O)N(C4=O)C3C(=O)NC(=O)CC3)=C2)CCOC1 JIGZJNQMIOEJSM-UHFFFAOYSA-N 0.000 claims 2
- HMQGMDOSEOPTJW-UHFFFAOYSA-N N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-[4-[[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]azetidin-3-yl]methyl]piperazin-1-yl]-2-(oxan-4-ylamino)benzamide Chemical compound O=C1C(N2C(=O)C3=CC(N4CC(CN5CCN(CC5)C5=CC=C(C(=O)NC=6C7=CC(=CC=C7NN=6)CC6=CC(=CC(=C6)F)F)C(NC6CCOCC6)=C5)C4)=CC=C3C2=O)CCC(=O)N1 HMQGMDOSEOPTJW-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 108091005682 Receptor kinases Proteins 0.000 claims 2
- 102000005937 Tropomyosin Human genes 0.000 claims 2
- 108010030743 Tropomyosin Proteins 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 1
- APRUIDKBAJQJRN-XGDNGBMYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[2-[4-[6-[6-[(2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]piperazin-1-yl]ethylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)NCCN1CCN(CC1)C1=NC(=CC=C1)C1=CN=C2N1N=C(C=C2)N1[C@H](CCC1)C1=CC(=CC=C1)F)=O)=O APRUIDKBAJQJRN-XGDNGBMYSA-N 0.000 claims 1
- GATVUHGZGNWIHZ-PBBFAOSKSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[2-[4-[6-[6-[(2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]piperazin-1-yl]-2-oxoethyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)NCC(=O)N1CCN(CC1)C1=NC(=CC=C1)C1=CN=C2N1N=C(C=C2)N1[C@H](CCC1)C1=CC(=CC=C1)F)=O)=O GATVUHGZGNWIHZ-PBBFAOSKSA-N 0.000 claims 1
- HAOMASYZSUGNTB-BONSOQDYSA-N 3-[5-[3-[4-[6-[6-[(2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]piperazin-1-yl]propyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC=1C=C(C=CC=1)[C@@H]1N(CCC1)C=1C=CC=2N(N=1)C(=CN=2)C1=CC=CC(=N1)N1CCN(CC1)CCCC1=CC=C2CN(C(C2=C1)=O)C1C(NC(CC1)=O)=O HAOMASYZSUGNTB-BONSOQDYSA-N 0.000 claims 1
- MDRMKDKRQWVBFF-BONSOQDYSA-N 3-[6-[3-[4-[6-[6-[(2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]piperazin-1-yl]propyl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC=1C=C(C=CC=1)[C@@H]1N(CCC1)C=1C=CC=2N(N=1)C(=CN=2)C1=CC=CC(=N1)N1CCN(CC1)CCCC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O MDRMKDKRQWVBFF-BONSOQDYSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010067601 Dysmyelination Diseases 0.000 claims 1
- FKUUPOKOGMWVTB-BONSOQDYSA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N1CC(C1)CN1CCN(CC1)C1=NC(=CC=C1)C1=CN=C2N1N=C(C=C2)N1[C@H](CCC1)C1=CC(=CC=C1)F)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N1CC(C1)CN1CCN(CC1)C1=NC(=CC=C1)C1=CN=C2N1N=C(C=C2)N1[C@H](CCC1)C1=CC(=CC=C1)F)=O)=O FKUUPOKOGMWVTB-BONSOQDYSA-N 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
Claims (15)
前記TRKリガンドが式1の部分を含み、
XはCR’R”であり、
R’とR”は独立して、水素、ハロゲン、OH、およびC 1 -C 8 アルキルから選択され、
Rは随意に置換されたアリールであり、
R 1 、R 2 、およびR 3 は独立して水素であり、
R 4 は前記二価化合物のリンカー部分に接続されるとともに、単結合、随意に置換されたC 3 -C 8 シクロアルキル、および随意に置換された3~8員のヘテロシクリルから選択され、
Arは、水素、ハロゲン、CN、NO 2 、OR 12 、NR 13 R 14 、NR 13 COR 14 、C 3 -C 8 シクロアルキル、および3~8員のヘテロシクリルから独立して選択される1つ以上の置換基で随意に置換されたアリールであり、
R 12 、R 13 、およびR 14 は独立して、水素、C 1 -C 8 アルキル、C 3 -C 8 シクロアルキル、C 3 -C 8 シクロアルコキシ、および3~8員のヘテロシクリルから選択され、または、
R 13 とR 14 は、それらが接続される原子と一体となって4~8員のシクロアルキル環あるいはヘテロシクリル環を形成し、
前記リンカー部分が式9のものであり、
A、W、およびBは、それぞれの出現時に独立して、ヌル、あるいは、R’-R’’、R’COR’’、R’CO 2 R’’、R’C(O)N(R 1 )R’’、R’OR’’、R’OC(O)R’’、R’OC(O)OR’’、R’OCON(R 1 )R’’、R’N(R 1 )R’’、R’NR 1 COR’’、R’NR 1 C(O)OR’’、および、R’NR 1 CON(R 2 )R’’から選択された二価部分から選択され、
R’およびR’’は独立して、ヌル、R r -(C 1 -C 8 アルキル)、C 1 -C 8 アルキレン、C 2 -C 8 アルケニレン、C 2 -C 8 アルキニレン、C 1 -C 8 ヒドロキシアルキレン、C 1 -C 8 ハロアルキレン、3~10員のカルボシクリル、および4~10員のヘテロシクリルから選択され、
R r は3~10員のカルボシクリルおよび4~10員のヘテロシクリルから選択され、
R 1 とR 2 は、水素とC 1 -C 8 アルキルから独立して選択され、ならびに、
mは0~15であり、ならびに、
前記分解タグは式5Bの部分であり、
V、W、およびXは独立してCR 2 であり、
YはCOとCR 3 R 4 から選択され、
Zは、ヌル、CO、CR 5 R 6 、NR 5 、O、随意に置換されたC 1 -C 10 アルキレン、随意に置換されたC 1 -C 10 アルケニレン、随意に置換されたC 1 -C 10 アルキニレン、随意に置換された3~10員のカルボシクリル、および随意に置換された4~10員のヘテロシクリルから選択され、
R 1 とR 2 は水素であり、
R 3 とR 4 は水素であり、ならびに、
R 5 とR 6 は水素である、二価化合物、またはその薬学的に許容可能な塩。 A bivalent compound, or a pharmaceutically acceptable salt thereof, comprising a tropomyosin receptor kinase (TRK) ligand conjugated to a degradation tag via a linker moiety , wherein
said TRK ligand comprises a moiety of Formula 1;
X is CR'R",
R′ and R″ are independently selected from hydrogen, halogen, OH, and C 1 -C 8 alkyl;
R is optionally substituted aryl;
R 1 , R 2 , and R 3 are independently hydrogen;
R 4 is attached to the linker moiety of said divalent compound and is selected from a single bond, optionally substituted C3 - C8 cycloalkyl, and optionally substituted 3-8 membered heterocyclyl ;
Ar is one or more independently selected from hydrogen, halogen, CN, NO 2 , OR 12 , NR 13 R 14 , NR 13 COR 14 , C 3 -C 8 cycloalkyl, and 3-8 membered heterocyclyl; aryl optionally substituted with the substituents of
R 12 , R 13 and R 14 are independently selected from hydrogen, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkoxy and 3-8 membered heterocyclyl; or,
R 13 and R 14 together with the atoms to which they are connected form a 4- to 8-membered cycloalkyl or heterocyclyl ring,
wherein said linker moiety is of Formula 9;
A, W, and B are independently on each occurrence null or R′—R″, R′COR″, R′CO 2 R″, R′C(O)N(R 1 ) R'', R'OR'', R'OC(O)R'', R'OC(O)OR'', R'OCON(R 1 )R'', R'N(R 1 ) a divalent moiety selected from R'', R'NR 1 COR'', R'NR 1 C(O)OR'', and R'NR 1 CON(R 2 )R'';
R′ and R″ are independently null, R r —(C 1 -C 8 alkyl), C 1 -C 8 alkylene, C 2 -C 8 alkenylene, C 2 -C 8 alkynylene, C 1 -C 8 hydroxyalkylene, C 1 -C 8 haloalkylene, 3-10 membered carbocyclyl, and 4-10 membered heterocyclyl;
R r is selected from 3-10 membered carbocyclyl and 4-10 membered heterocyclyl;
R 1 and R 2 are independently selected from hydrogen and C 1 -C 8 alkyl, and
m is 0-15, and
the resolution tag is part of Formula 5B;
V, W, and X are independently CR2 ;
Y is selected from CO and CR3R4 ;
Z is null, CO, CR 5 R 6 , NR 5 , O, optionally substituted C 1 -C 10 alkylene, optionally substituted C 1 -C 10 alkenylene, optionally substituted C 1 -C 10alkynylene , optionally substituted 3-10 membered carbocyclyl, and optionally substituted 4-10 membered heterocyclyl;
R 1 and R 2 are hydrogen;
R 3 and R 4 are hydrogen, and
A divalent compound, or a pharmaceutically acceptable salt thereof, wherein R5 and R6 are hydrogen .
* は前記二価化合物のリンカー部分への接続部を示し、
R a はNR 13 R 14 とNR 13 COR 14 から選択され、
R 13 とR 14 は独立して、水素、C 1 -C 8 アルキル、C 3 -C 8 シクロアルキル、C 3 -C 8 シクロアルコキシ、および3~8員のヘテロシクリルから選択され、あるいは、
R 13 とR 14 は、それらが接続される原子と一体となって4~8員のシクロアルキル環またはヘテロシクリル環を形成する、請求項1に記載の二価化合物、またはその薬学的に許容可能な塩。 R 4 -Ar is part of formula A1;
* indicates the connection to the linker moiety of the divalent compound,
R a is selected from NR 13 R 14 and NR 13 COR 14 ;
R 13 and R 14 are independently selected from hydrogen, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkoxy and 3-8 membered heterocyclyl, or
2. The divalent compound of claim 1, wherein R 13 and R 14 together with the atoms to which they are attached form a 4- to 8-membered cycloalkyl or heterocyclyl ring, or a pharmaceutically acceptable compound thereof. salt.
2-(2,6-ジオキソピペリジン-3-イル)-5-((2-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)-2-オキソエチル)アミノ)イソインドリン-1,3-ジオン(TR-123)、2-(2,6-dioxopiperidin-3-yl)-5-((2-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl) imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)amino)isoindoline-1,3-dione (TR-123),
2-(2,6-ジオキソピペリジン-3-イル)-5-(3-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)プロピル)イソインドリン-1,3-ジオン(TR-172)、 2-(2,6-dioxopiperidin-3-yl)-5-(3-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo) [1,2-b]pyridazin-3-yl)pyridin-2-yl)piperazin-1-yl)propyl)isoindoline-1,3-dione (TR-172),
2-(2,6-ジオキソピペリジン-3-イル)-5-(2-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)エトキシ)イソインドリン-1,3-ジオン(TR-173)、 2-(2,6-dioxopiperidin-3-yl)-5-(2-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo) [1,2-b]pyridazin-3-yl)pyridin-2-yl)piperazin-1-yl)ethoxy)isoindoline-1,3-dione (TR-173),
2-(2,6-ジオキソピペリジン-3-イル)-5-((2-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)エチル)アミノ)イソインドリン-1,3-ジオン(TR-181)、 2-(2,6-dioxopiperidin-3-yl)-5-((2-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl) imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)piperazin-1-yl)ethyl)amino)isoindoline-1,3-dione (TR-181),
3-(6-(3-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)プロピル)-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン(TR-185)、 3-(6-(3-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl) pyridin-2-yl)piperazin-1-yl)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (TR-185),
3-(5-(3-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)プロピル)-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン(TR-186)、 3-(5-(3-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl) pyridin-2-yl)piperazin-1-yl)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (TR-186),
3-(5-((2-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)エチル)アミノ)-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン(TR-191)、 3-(5-((2-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl) )pyridin-2-yl)piperazin-1-yl)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (TR-191),
3-(6-((2-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)エチル)アミノ)-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン(TR-196)、 3-(6-((2-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl) )pyridin-2-yl)piperazin-1-yl)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (TR-196),
2-(2,6-ジオキソピペリジン-3-イル)-5-(3-((4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)メチル)アゼチジン-1-イル)イソインドリン-1,3-ジオン(TR-198)、 2-(2,6-dioxopiperidin-3-yl)-5-(3-((4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl) imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)piperazin-1-yl)methyl)azetidin-1-yl)isoindoline-1,3-dione (TR-198),
3-(6-(3-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)-3-オキソプロプ-1-イン-1-イル)-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン(TR-202) 3-(6-(3-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl) Pyridin-2-yl)piperazin-1-yl)-3-oxoprop-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (TR-202)
3-(5-(3-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)-3-オキソプロプ-1-イン-1-イル)-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン(TR-203) 3-(5-(3-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl) Pyridin-2-yl)piperazin-1-yl)-3-oxoprop-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (TR-203)
2-(2,6-ジオキソピペリジン-3-イル)-5-(2-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)エチル)イソインドリン-1,3-ジオン(TR-204) 2-(2,6-dioxopiperidin-3-yl)-5-(2-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo) [1,2-b]pyridazin-3-yl)pyridin-2-yl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (TR-204)
2-(2,6-ジオキソピペリジン-3-イル)-5-(3-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-カルボニル)アゼチジン-1-イル)イソインドリン-1,3-ジオン(TR-211) 2-(2,6-dioxopiperidin-3-yl)-5-(3-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo) [1,2-b]pyridazin-3-yl)pyridin-2-yl)piperazin-1-carbonyl)azetidin-1-yl)isoindoline-1,3-dione (TR-211)
2-(2,6-ジオキソピペリジン-3-イル)-5-(3-((4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)メチル)ピロリジン-1-イル)イソインドリン-1,3-ジオン(TR-225) 2-(2,6-dioxopiperidin-3-yl)-5-(3-((4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl) imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)isoindoline-1,3-dione (TR-225)
N-[5-[(3,5-ジフルオロフェニル)メチル]-1H-インダゾール-3-イル]-4-[4-[[1-[2-(2,6-ジオキソ-3-ピペリジル)-1,3-ジオキソ-イソインドリン-5-イル]アゼチジン-3-イル]メチル]ピペラジン-1-イル]-2-(テトラヒドロピラン-4-イルアミノ)ベンズアミド(TR-231) N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-[4-[[1-[2-(2,6-dioxo-3-piperidyl)- 1,3-dioxo-isoindolin-5-yl]azetidin-3-yl]methyl]piperazin-1-yl]-2-(tetrahydropyran-4-ylamino)benzamide (TR-231)
N-[5-[(3,5-ジフルオロフェニル)メチル]-1H-インダゾール-3-イル]-4-[4-[2-[[2-(2,6-ジオキソ-3-ピペリジル)-1,3-ジオキソ-イソインドリン-5-イル]アミノ]エチル]ピペラジン-1-イル]-2-(テトラヒドロピラン-4-イルアミノ)ベンズアミド(TR-232) N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-[4-[2-[[2-(2,6-dioxo-3-piperidyl)- 1,3-dioxo-isoindolin-5-yl]amino]ethyl]piperazin-1-yl]-2-(tetrahydropyran-4-ylamino)benzamide (TR-232)
N-(2-(2,6-ジオキソピペリジン-3-イル)-1,3-ジオキソイソインドリン-5-イル)-2-(4-(6-(6-((R)-2-(3-フルオロフェニル)ピロリジン-1-イル)イミダゾ[1,2-b]ピリダジン-3-イル)ピリジン-2-イル)ピペラジン-1-イル)アセトアミド(TR-233)、またはその薬学的に許容可能な塩からなる群から選択される、請求項1に記載の二価化合物、またはその薬学的に許容可能な塩。 N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-(4-(6-(6-((R)-2 -(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)piperazin-1-yl)acetamide (TR-233), or its pharmaceutical 2. The divalent compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of salts acceptable for:
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2018/101715 | 2018-08-22 | ||
CN2018101715 | 2018-08-22 | ||
CNPCT/CN2019/086894 | 2019-05-14 | ||
CN2019086894 | 2019-05-14 | ||
PCT/CN2019/101850 WO2020038415A1 (en) | 2018-08-22 | 2019-08-21 | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021535104A JP2021535104A (en) | 2021-12-16 |
JPWO2020038415A5 true JPWO2020038415A5 (en) | 2022-08-29 |
JP7472103B2 JP7472103B2 (en) | 2024-04-22 |
Family
ID=69592803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021509151A Active JP7472103B2 (en) | 2018-08-22 | 2019-08-21 | Tropomyosin receptor kinase (TRK) degrading compounds and methods of use thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210363146A1 (en) |
EP (1) | EP3841098A4 (en) |
JP (1) | JP7472103B2 (en) |
KR (1) | KR20210069634A (en) |
CN (2) | CN112888681A (en) |
AU (1) | AU2019323446A1 (en) |
BR (1) | BR112021003098A2 (en) |
CA (1) | CA3110267A1 (en) |
IL (1) | IL280984A (en) |
MX (1) | MX2021001957A (en) |
WO (1) | WO2020038415A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
GB201820165D0 (en) | 2018-12-11 | 2019-01-23 | Ucb Biopharma Sprl | Therapeutic agents |
US20230219945A1 (en) * | 2019-12-17 | 2023-07-13 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
IL295799A (en) * | 2020-02-26 | 2022-10-01 | Cullgen Shanghai Inc | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
IL296451A (en) * | 2020-03-19 | 2022-11-01 | Kymera Therapeutics Inc | Mdm2 degraders and uses thereof |
US20230167081A1 (en) * | 2020-04-30 | 2023-06-01 | President And Fellows Of Harvard College | 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders |
WO2021226262A1 (en) | 2020-05-06 | 2021-11-11 | Nurix Therapeutics, Inc. | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof |
CN113801062B (en) * | 2020-06-15 | 2023-05-26 | 沈阳药科大学 | Preparation method of 3-amino-5- (3, 5-difluorobenzyl) -1H-indazole |
CN112125977B (en) * | 2020-09-29 | 2022-03-08 | 西安交通大学 | TWEAK-MV1 coupled protein and application thereof in psoriasis resistance |
CN116583509A (en) * | 2020-10-07 | 2023-08-11 | 上海睿跃生物科技有限公司 | Compounds and methods for treating cancer |
MX2023008296A (en) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Isoindolinone compounds. |
US20240246955A1 (en) * | 2021-04-12 | 2024-07-25 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
CN113402467B (en) * | 2021-06-18 | 2022-05-13 | 山东汇海医药化工有限公司 | Synthetic method of flibanserin |
CA3223447A1 (en) | 2021-06-25 | 2022-12-29 | Korea Research Institute Of Chemical Technology | Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof |
CN113278023B (en) * | 2021-07-22 | 2021-10-15 | 上海睿跃生物科技有限公司 | Nitrogen-containing heterocyclic compound and preparation method and application thereof |
CN116003418A (en) * | 2021-10-22 | 2023-04-25 | 标新生物医药科技(上海)有限公司 | CRBN E3 ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof |
EP4180428A1 (en) | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
CN114230518A (en) * | 2021-12-13 | 2022-03-25 | 海南梵圣生物科技有限公司 | Preparation method of 5-benzyl-1H-indazole-3-amine compound |
WO2023116835A1 (en) * | 2021-12-24 | 2023-06-29 | 苏州开拓药业股份有限公司 | Multi-protein degradation agent having imide skeleton |
WO2023239629A1 (en) | 2022-06-06 | 2023-12-14 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade cdk2 |
WO2023249994A1 (en) * | 2022-06-22 | 2023-12-28 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
CN117510504A (en) * | 2022-08-05 | 2024-02-06 | 深圳市新樾生物科技有限公司 | Protein kinase degradation agent, medicine and application |
WO2024149365A1 (en) * | 2023-01-13 | 2024-07-18 | Shenzhen Newdel Biotech Co., Ltd. | Salts and crystalline forms of compound a, methods of preparation, and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015112445A1 (en) * | 2014-01-24 | 2015-07-30 | Abbvie Inc. | 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use |
WO2015143652A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
KR20240038809A (en) * | 2014-04-14 | 2024-03-25 | 아비나스 오퍼레이션스, 인코포레이티드 | Imide-based modulators of proteolysis and associated methods of use |
EP3233840B1 (en) * | 2014-12-16 | 2018-11-21 | Eudendron S.r.l. | Heterocyclic derivatives modulating activity of certain protein kinases |
EP3270917A4 (en) * | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
CN108366992A (en) * | 2015-11-02 | 2018-08-03 | 耶鲁大学 | Proteolysis targets chimera compound and its methods for making and using same |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109790143A (en) * | 2016-05-10 | 2019-05-21 | C4医药公司 | The C of amine connection for target protein degradation3Glutarimide degron body |
WO2017197055A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3725771A4 (en) * | 2017-12-13 | 2021-10-13 | Shanghaitech University | Alk protein degradation agent and anti-tumor application thereof |
US11969472B2 (en) * | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
IL295799A (en) * | 2020-02-26 | 2022-10-01 | Cullgen Shanghai Inc | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
-
2019
- 2019-08-21 WO PCT/CN2019/101850 patent/WO2020038415A1/en unknown
- 2019-08-21 EP EP19852808.5A patent/EP3841098A4/en active Pending
- 2019-08-21 CA CA3110267A patent/CA3110267A1/en active Pending
- 2019-08-21 US US17/269,670 patent/US20210363146A1/en active Pending
- 2019-08-21 AU AU2019323446A patent/AU2019323446A1/en active Pending
- 2019-08-21 CN CN201980067402.4A patent/CN112888681A/en active Pending
- 2019-08-21 MX MX2021001957A patent/MX2021001957A/en unknown
- 2019-08-21 KR KR1020217008232A patent/KR20210069634A/en unknown
- 2019-08-21 CN CN202210693243.2A patent/CN115626927B/en active Active
- 2019-08-21 JP JP2021509151A patent/JP7472103B2/en active Active
- 2019-08-21 BR BR112021003098-0A patent/BR112021003098A2/en unknown
-
2021
- 2021-02-21 IL IL280984A patent/IL280984A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2020038415A5 (en) | ||
JP2007504160A5 (en) | ||
JP2014511869A5 (en) | ||
JP2004517049A5 (en) | ||
JP2009526072A5 (en) | ||
JP2004525179A5 (en) | ||
JP2008536825A5 (en) | ||
IL295799A (en) | Tropomyosin receptor kinase (trk) degradation compounds and methods of use | |
RU2009125019A (en) | CARBONIC ACID DERIVATIVES | |
JP2002505286A5 (en) | ||
RU2008112221A (en) | COMPOUNDS OF A NUMBER OF ISOINDOLIMIDES, THEIR COMPOSITIONS AND METHODS OF APPLICATION | |
RU2003129502A (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, APPLICATION, METHOD FOR PREVENTING OR TREATING DISEASES | |
JP2003510359A5 (en) | ||
RU2218337C2 (en) | Derivatives of thiazole, method for their preparing and pharmaceutical composition based on thereof | |
JP2017537948A5 (en) | ||
JP2006507355A5 (en) | ||
JP2002030084A5 (en) | ||
JP2020533352A5 (en) | ||
JP2021500332A5 (en) | ||
RU99100277A (en) | TIAZOLE DERIVATIVES | |
JP2013515040A5 (en) | ||
JP2018515489A5 (en) | ||
JPWO2021170109A5 (en) | ||
JP2014511865A5 (en) | ||
JP2004524279A5 (en) |